IL324676A - טיפול בזאבת - Google Patents

טיפול בזאבת

Info

Publication number
IL324676A
IL324676A IL324676A IL32467625A IL324676A IL 324676 A IL324676 A IL 324676A IL 324676 A IL324676 A IL 324676A IL 32467625 A IL32467625 A IL 32467625A IL 324676 A IL324676 A IL 324676A
Authority
IL
Israel
Prior art keywords
lupus
treatment
Prior art date
Application number
IL324676A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL324676A publication Critical patent/IL324676A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL324676A 2023-05-19 2025-11-16 טיפול בזאבת IL324676A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363503237P 2023-05-19 2023-05-19
PCT/IB2024/054759 WO2024241156A1 (en) 2023-05-19 2024-05-16 Treatment of lupus

Publications (1)

Publication Number Publication Date
IL324676A true IL324676A (he) 2026-01-01

Family

ID=91276835

Family Applications (1)

Application Number Title Priority Date Filing Date
IL324676A IL324676A (he) 2023-05-19 2025-11-16 טיפול בזאבת

Country Status (4)

Country Link
CN (1) CN121127499A (he)
AU (1) AU2024277546A1 (he)
IL (1) IL324676A (he)
WO (1) WO2024241156A1 (he)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2418220T1 (sl) 2003-12-10 2017-10-30 E. R. Squibb & Sons, L.L.C. Interferon alfa protitelesa in njihova uporaba
DK1781705T3 (en) 2004-06-21 2015-01-12 Squibb & Sons Llc Interferon-alpha receptor 1 antibodies and uses thereof
WO2009100309A2 (en) 2008-02-08 2009-08-13 Medimmune, Llc Anti-ifnar1 antibodies with reduced fc ligand affinity
US20120251546A1 (en) 2009-09-03 2012-10-04 Medimmune Llc Type 1 inteferon diagnostic
EP4233892A3 (en) 2015-08-19 2023-10-25 Astrazeneca AB Stable anti-ifnar1 formulation
CN106243226B (zh) 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
WO2021086991A1 (en) * 2019-10-30 2021-05-06 The Regents Of The University Of California Methods of treating systemic lupus erythematosus
AU2022260531B2 (en) 2021-04-23 2024-03-07 Astrazeneca Ab Anti-ifnar1 dosing regime for subcutaneous injection

Also Published As

Publication number Publication date
WO2024241156A1 (en) 2024-11-28
CN121127499A (zh) 2025-12-12
AU2024277546A1 (en) 2026-01-15

Similar Documents

Publication Publication Date Title
IL288011A (he) טיפול בזאבת אדמנתית עורית
IL315503A (he) שיטות לטיפול
IL324595A (he) שימוש במיקרו פפטיד miac
GB202201824D0 (en) Methods of treatment
IL320711A (he) שיטות טיפול
GB201907305D0 (en) Treatment of conditions
IL324676A (he) טיפול בזאבת
IL310241A (he) טיפול בלופוס
GB202201825D0 (en) Methods of treatment
GB202201819D0 (en) Methods of treatment
GB202102257D0 (en) Treatment of shells
CA3292620A1 (en) Treatment of lupus
HK40115317A (en) Treatment of lupus
HK40113692A (en) Treatment of lupus
GB202315695D0 (en) TReatment of cariomyopathy
GB202212506D0 (en) Treatment of covid-19
GB202307686D0 (en) Treatment of conditions
GB202101251D0 (en) Treatment of conditions
GB202118011D0 (en) Methods of treatment
GB202118007D0 (en) Methods of treatment
GB202118006D0 (en) Methods of treatment
GB202108242D0 (en) Methods of treatment
GB202108245D0 (en) Methods of treatment
IL325003A (he) טיפול באפילפסיה
IL321175A (he) שיטות טיפול עם טרדיפיטנט